Evidence map›Paper›PMID 38970700›Full record

ReviewProtoplasma2024

Harnessing the potential of microalgae for the production of monoclonal antibodies and other recombinant proteins.

Balwinder Kaur Rajput, Sana Fatima Ikram, Bhumi Nath Tripathi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Protoplasma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Balwinder Kaur RajputDepartment of Biotechnology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, 484887, India.
Sana Fatima IkramDepartment of Biotechnology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, 484887, India.
Bhumi Nath TripathiDepartment of Biotechnology, Indira Gandhi National Tribal University, Amarkantak, Madhya Pradesh, 484887, India. bhuminathtripathi@hotmail.com.ORCID http://orcid.org/0000-0001-9482-6935

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) have become indispensable tools in various fields, from research to therapeutics, diagnostics, and industries. However, their production, primarily in mammalian cell culture systems, is cost-intensive and resource-demanding. Microalgae, diverse photosynthetic microorganisms, are gaining attention as a favorable option for manufacturing mAbs and various other recombinant proteins. This review explores the potential of microalgae as a robust expression system for biomanufacturing high-value proteins. It also highlights the diversity of microalgae species suitable for recombinant protein. Nuclear and chloroplast genomes of some microalgae have been engineered to express mAbs and other valuable proteins. Codon optimization, vector construction, and other genetic engineering techniques have significantly improved recombinant protein expression in microalgae. These accomplishments demonstrate the potential of microalgae for biopharmaceutical manufacturing. Microalgal biotechnology holds promise for revolutionizing the production of mAbs and other therapeutic proteins, offering a sustainable and cost-effective solution to address critical healthcare needs.

Indexed as

Antibodies, MonoclonalMicroalgaeRecombinant ProteinsAnimalsBiotechnologyAntibodies, MonoclonalRecombinant ProteinsAlternative expression systemsMicroalgaeMonoclonal antibodiesRecombinant proteinsVector construction

Identifiers

PMID38970700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.